Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Sponsor type
Pharmaceutical company, Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
13/04/2026
Enrollment target
12
Sites
Spain
Condition studied
unresectable advanced or metastatic solid cancer
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.